Dyne Therapeutics, Inc.

General ticker "DYN" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $2.6B (TTM average)

Dyne Therapeutics, Inc. follows the US Stock Market performance with the rate: 3.5%.

Estimated limits based on current volatility of 4.8%: low 10.13$, high 11.16$

Factors to consider:

  • Earnings expected soon, date: 2025-05-01 bmo
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [10.86$, 27.32$]
  • 2025-12-31 to 2026-12-31 estimated range: [7.29$, 19.31$]

Financial Metrics affecting the DYN estimates:

  • Negative: Non-GAAP EPS, $ of -3.35 <= 0.04
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -10.29 <= 1.79
  • Negative: negative Operating income
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Positive: Inventory ratio change, % of 0 <= 0
  • Positive: Interest expense per share, $ of 0 <= 0
  • Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82
  • Negative: Industry earnings per price (median), % of -27.42 <= 0

Similar symbols

Short-term DYN quotes

2025-03-132025-03-142025-03-172025-03-182025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-2478910111213
Price $

Long-term DYN plot with estimates

51015202530354045Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−1−0.50
DYNS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $170.96MM $242.16MM $343.89MM
Operating Income $-170.96MM $-242.16MM $-343.89MM
Non-Operating Income $2.86MM $6.22MM $26.47MM
R&D Expense $142.76MM $210.76MM $281.41MM
Income(Loss) $-168.10MM $-235.94MM $-317.42MM
Profit(Loss)* $-165.24MM $-235.94MM $-317.42MM
Stockholders Equity $252.36MM $91.29MM $629.84MM
Assets $306.32MM $165.08MM $691.23MM
Operating Cash Flow $-153.65MM $-188.16MM $-292.37MM
Capital expenditure $3.07MM $0.73MM $2.38MM
Investing Cash Flow $87.20MM $83.31MM $-204.08MM
Financing Cash Flow $37.39MM $54.32MM $809.89MM
Earnings Per Share** $-3.18 $-3.95 $-3.37

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.